Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Mistry, Jayna J, Hellmich, Charlotte, Lambert, Amelia, Moore, Jamie A, Jibril, Aisha, Collins, Angela, Bowles, Kristian M, Rushworth, Stuart A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117650/
https://www.ncbi.nlm.nih.gov/pubmed/33985565
http://dx.doi.org/10.1186/s40364-021-00291-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117650/
https://www.ncbi.nlm.nih.gov/pubmed/33985565
http://dx.doi.org/10.1186/s40364-021-00291-y

Ejemplares similares